Screener
Charles River Laboratories CRL Impairment Charges
Impairment Charges at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:ImpairmentOfLongLivedAssetsHeldForUse.
The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:21 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001100682-26-000118
| Line item | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
|---|---|---|
| Net income (loss) | $(15,562) | $78,571 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
| Depreciation and amortization | 134,441 | 239,871 |
| Long-lived asset impairments | 26,279 | 31,203 |
| Stock-based compensation | 42,162 | 30,184 |
| Deferred income taxes | 12,077 | (41,030) |
| Write down of inventories | 3,165 | 11,067 |
| (Gains) losses and impairments on venture capital and strategic equity investments, net | (6,936) | 12,899 |
Item 1. Financial Statements
FAQ
- What is Charles River Laboratories's impairment charges?
- Charles River Laboratories (CRL) reported impairment charges of $10.42M in Q2 2026.
- How has Charles River Laboratories's impairment charges changed year-over-year?
- Charles River Laboratories's impairment charges decreased by 49.5% year-over-year, from $20.63M to $10.42M.
- What is the long-term trend for Charles River Laboratories's impairment charges?
- Over 3 years (2021 to 2025), Charles River Laboratories's impairment charges has grown at a 508.3% compound annual growth rate (CAGR), from $733K to $165M.
- What does impairment charges mean?
- Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.
Ask your AI about Charles River Laboratories's impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude